Preventive effect of Hangeshashin-to against oral mucositis in allogeneic hematopoietic stem cell transplantatio

Not Applicable

• Conditions: Patients who receive their first allogeneic hematopoietic stem cell transplantation

• Registration Number: JPRN-UMIN000011015
• Lead Sponsor: Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-12-01
• Study Completion: 2014-05-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients who are not eligible for HSCT 2)Allergy to Hangeshashin-to 3)Patients who cannot take medicine orally, or have grade 2 or more oral mucositis at the start of conditioning regimen 4)Aldosteronism 5)Myopathy 6)Uncontrollable hypokalemia (<3.5 mEq/L) 7)Inadequate condition as diagnosed by primary physician

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cumulative incidence of grade 2 or more oral mucositis between the start of conditioning regimen and engraftment

Secondary Outcome Measures

Name	Time	Method
1)Incidence and severity of diarrhea 2)Incidence and duration of febrile neutropenia 3)Frequency and duration of use of intravenous hyperalimentation 4)Duration of engraftment 5)Incidence and severity of acute graft-versus-host disease